$NEO
NEOGENOMICS INC Stock $neo

$neo Overview Financials Valuation SEC Filings Company Website

2016 Q3 Form 10-Q Financial Statement

#000156459016027730 Filed on November 07, 2016

Income Statement

Concept	2016 Q3	2015 Q4	2015 Q3
Revenue	$60.76M	$27.28M	$25.13M
YoY Change	141.83%	9.12%	8.22%
Cost Of Revenue	$33.42M	$15.10M	$13.96M
YoY Change	139.46%	11.85%	7.99%
Gross Profit	$27.35M	$12.23M	$11.17M
YoY Change	144.79%	6.59%	8.52%
Gross Profit Margin	45.0%	44.82%	44.46%
Selling, General & Admin	$24.98M	$15.60M	$10.19M
YoY Change	145.27%	60.82%	8.91%
% of Gross Profit	91.36%	127.58%	91.18%
Research & Development	$967.0K	$1.900M	$871.0K
YoY Change	11.02%	375.0%	-14.1%
% of Gross Profit	3.54%	15.54%	7.8%
Depreciation & Amortization	$6.030M	$1.890M	$1.810M
YoY Change	233.15%	25.17%	11.04%
% of Gross Profit	22.05%	15.46%	16.2%
Operating Expenses	$25.95M	$17.40M	$11.06M
YoY Change	134.69%	70.59%	6.66%
Operating Profit	$1.395M	-$5.172M	$114.0K
YoY Change	1123.68%	-506.6%	-256.16%
Interest Expense	-$1.500M	-$200.0K	-$200.0K
YoY Change	650.0%	0.0%	0.0%
% of Operating Profit	-107.53%		-175.44%
Other Income/Expense, Net		$2.000M	-$239.0K
YoY Change			9.63%
Pretax Income	-$73.00K	-$3.400M	-$125.0K
YoY Change	-41.6%	-409.09%	-57.04%
Income Tax	-$6.000K	-$2.000M	$0.00
% Of Pretax Income
Net Earnings	-$67.00K	-$1.473M	-$125.0K
YoY Change	-46.4%	-240.69%	-57.04%
Net Earnings / Revenue	-0.11%	-5.4%	-0.5%
Basic Earnings Per Share	-$0.07	-$0.03	$0.00
Diluted Earnings Per Share	-$0.07	-$0.03	$0.00
COMMON SHARES
Basic Shares Outstanding	78.15M	60.86M	60.54M
Diluted Shares Outstanding	78.15M	60.86M	60.54M

Balance Sheet

Concept	2016 Q3	2015 Q4	2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$28.90M	$23.40M	$34.00M
YoY Change	-15.0%	-30.56%	-1.16%
Cash & Equivalents	$28.94M	$23.42M	$33.97M
Short-Term Investments
Other Short-Term Assets	$7.500M	$4.900M	$2.400M
YoY Change	212.5%	145.0%	50.0%
Inventory	$6.000M	$5.108M	$2.967M
Prepaid Expenses
Receivables	$50.20M	$48.94M	$21.56M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$92.56M	$99.03M	$60.86M
YoY Change	52.09%	68.58%	6.31%
LONG-TERM ASSETS
Property, Plant & Equipment	$34.17M	$34.58M	$15.90M
YoY Change	114.93%	129.26%	8.62%
Goodwill	$146.2M	$147.0M	$2.929M
YoY Change	4890.75%	4919.43%	14.37%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$174.0K	$129.0K	$129.0K
YoY Change	34.88%	-8.51%	-9.79%
Total Long-Term Assets	$262.9M	$268.9M	$22.88M
YoY Change	1048.7%	1102.5%	6.06%
TOTAL ASSETS
Total Short-Term Assets	$92.56M	$99.03M	$60.86M
Total Long-Term Assets	$262.9M	$268.9M	$22.88M
Total Assets	$355.4M	$368.0M	$83.74M
YoY Change	324.44%	353.67%	6.24%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$13.98M	$12.46M	$5.026M
YoY Change	178.23%	98.03%	-20.06%
Accrued Expenses	$15.80M	$13.60M	$6.100M
YoY Change	159.02%	1025.83%	454.55%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$8.900M	$0.00
YoY Change
Long-Term Debt Due	$646.0K	$600.0K	$4.200M
YoY Change	-84.62%	-81.25%	31.25%
Total Short-Term Liabilities	$35.39M	$40.06M	$15.33M
YoY Change	130.9%	173.94%	9.85%
LONG-TERM LIABILITIES
Long-Term Debt	$52.19M	$52.34M	$5.700M
YoY Change	815.68%	887.47%	9.62%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$73.94M	$73.12M	$6.564M
YoY Change	1026.49%	1102.98%	13.15%
TOTAL LIABILITIES
Total Short-Term Liabilities	$35.39M	$40.06M	$15.33M
Total Long-Term Liabilities	$73.94M	$73.12M	$6.564M
Total Liabilities	$109.3M	$113.2M	$21.89M
YoY Change	399.43%	446.71%	10.82%
SHAREHOLDERS EQUITY
Retained Earnings	-$38.26M	-$21.94M	-$20.47M
YoY Change	86.94%	13.06%	0.08%
Common Stock	$239.0M	$231.5M	$82.32M
YoY Change	190.31%	190.06%	3.52%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$200.8M	$208.5M	$61.85M
YoY Change
Total Liabilities & Shareholders Equity	$355.4M	$351.3M	$83.74M
YoY Change	324.44%	333.12%	6.24%

Cashflow Statement

Concept	2016 Q3	2015 Q4	2015 Q3
OPERATING ACTIVITIES
Net Income	-$67.00K	-$1.473M	-$125.0K
YoY Change	-46.4%	-240.69%	-57.04%
Depreciation, Depletion And Amortization	$6.030M	$1.890M	$1.810M
YoY Change	233.15%	25.17%	11.04%
Cash From Operating Activities	$9.620M	$2.120M	$2.370M
YoY Change	305.91%	114.14%	-25.0%
INVESTING ACTIVITIES
Capital Expenditures	-$1.900M	-$540.0K	-$500.0K
YoY Change	280.0%	-48.57%	-33.33%
Acquisitions
YoY Change
Other Investing Activities		-$72.94M
YoY Change
Cash From Investing Activities	-$1.900M	-$73.48M	-$500.0K
YoY Change	280.0%	6898.1%	-92.4%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-580.0K	60.80M	-860.0K
YoY Change	-32.56%	-10067.21%	-102.63%
NET CHANGE
Cash From Operating Activities	9.620M	2.120M	2.370M
Cash From Investing Activities	-1.900M	-73.48M	-500.0K
Cash From Financing Activities	-580.0K	60.80M	-860.0K
Net Change In Cash	7.140M	-10.56M	1.010M
YoY Change	606.93%	1476.12%	-96.56%
FREE CASH FLOW
Cash From Operating Activities	$9.620M	$2.120M	$2.370M
Capital Expenditures	-$1.900M	-$540.0K	-$500.0K
Free Cash Flow	$11.52M	$2.660M	$2.870M
YoY Change	301.39%	30.39%	-26.6%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-21941000
	us-gaap	Gross Profit GrossProfit	31528000
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2016Q3	us-gaap	Goodwill Goodwill	146179000
CY2016Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	4380000
CY2016Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	11382000
CY2016Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	13984000
CY2016Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	82346000
CY2016Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7488000
CY2016Q3	us-gaap	Assets Current AssetsCurrent	92559000
CY2016Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	174000
CY2016Q3	us-gaap	Assets Assets	355427000
	dei	Amendment Flag AmendmentFlag	false
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	209510000
CY2016Q3	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	78000
CY2015Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	76000
CY2016Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	34169000
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	26534000
CY2016Q3	us-gaap	Gross Profit GrossProfit	27345000
CY2016Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	355427000
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	351287000
CY2016Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	37840000
CY2016Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	238975000
CY2015Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	231375000
CY2016Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-38263000
CY2016Q3	us-gaap	Stockholders Equity StockholdersEquity	200790000
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000
	neo	Clinical Testing Revenue ClinicalTestingRevenue	71770000
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.21
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2016-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
CY2016Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
	dei	Entity Registrant Name EntityRegistrantName	NEOGENOMICS INC
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2015Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	73117000
CY2016Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	73943000
CY2016Q3	us-gaap	Liabilities Liabilities	109335000
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2016Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	78512921
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	23420000
CY2016Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2016Q3	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	5513000
CY2016Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	52194000
CY2016Q3	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	16236000
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2015Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	48943000
CY2015Q4	us-gaap	Inventory Net InventoryNet	5108000
	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	183593000
CY2016Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	11056000
	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	72523000
	us-gaap	Cost Of Services CostOfServices	100471000
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
	dei	Trading Symbol TradingSymbol	NEO
	dei	Entity Central Index Key EntityCentralIndexKey	0001077183
CY2016Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	646000
CY2016Q3	us-gaap	Liabilities Current LiabilitiesCurrent	35392000
CY2015Q4	us-gaap	Liabilities Liabilities	113175000
CY2016Q3	us-gaap	Redeemable Noncontrolling Interest Equity Preferred Carrying Amount RedeemableNoncontrollingInterestEquityPreferredCarryingAmount	45302000
CY2015Q3	us-gaap	Cost Of Services CostOfServices	13955000
CY2015Q4	us-gaap	Redeemable Noncontrolling Interest Equity Preferred Carrying Amount RedeemableNoncontrollingInterestEquityPreferredCarryingAmount	28602000
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
	us-gaap	Cost Of Services CostOfServices	40995000
	us-gaap	Gross Profit GrossProfit	83122000
CY2015Q3	us-gaap	Gross Profit GrossProfit	11171000
CY2016Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	19025000
	neo	Clinical Testing Revenue ClinicalTestingRevenue	166674000
CY2016Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000
CY2016Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	78494022
CY2015Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
CY2015Q3	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	25126000
CY2016Q3	us-gaap	Cost Of Services CostOfServices	33416000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	60414000
CY2015Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	60537000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	77224000
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	77224000
CY2015Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	60537000
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	60414000
	us-gaap	Depreciation Depreciation	11550000
	us-gaap	Depreciation Depreciation	4971000
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5454000
CY2015Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2748000
CY2016Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-1468000
CY2015Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-239000
CY2015Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	871000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3719000
CY2015Q3	us-gaap	Operating Expenses OperatingExpenses	11057000
	us-gaap	Operating Expenses OperatingExpenses	77613000
CY2016Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-6000
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	1395000
CY2016Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	5958000
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	114000
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-623000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	55810000
CY2016Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-73000
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	967000
CY2015Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-125000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	21036000
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-4509000
CY2016Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5634000
CY2016Q3	neo	Amortization Of Preferred Stock Beneficial Conversion Feature AmortizationOfPreferredStockBeneficialConversionFeature	3727000
CY2015Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-125000
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-67000
CY2015Q4	us-gaap	Line Of Credit LineOfCredit	8869000
CY2015Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	600000
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	40058000
CY2015Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	5040000
CY2015Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	52336000
CY2015Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	15741000
CY2015Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	4759000
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	75820307
CY2016Q3	neo	Pharma Services And Research Revenue PharmaServicesAndResearchRevenue	5022000
CY2015Q3	neo	Pharma Services And Research Revenue PharmaServicesAndResearchRevenue	251000
	neo	Pharma Services And Research Revenue PharmaServicesAndResearchRevenue	16919000
	neo	Pharma Services And Research Revenue PharmaServicesAndResearchRevenue	753000
CY2015Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7438000
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	25950000
CY2016Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
CY2015Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.21
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	283000
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	532000
	neo	Share Based Compensation And Warrants ShareBasedCompensationAndWarrants	4024000
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	8183000
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1849000
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	409000
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	46000
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-12000
	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	3271000
	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	2000
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	21718000
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	4272000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5328000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1682000
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-5328000
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-1682000
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	10044000
	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	413000
	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	3874000
	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	2912000
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	3456000
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	599000
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-10875000
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-2313000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	5515000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	277000
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	33689000
CY2015Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	33966000
	us-gaap	Interest Paid InterestPaid	3993000
	us-gaap	Interest Paid InterestPaid	672000
	us-gaap	Income Taxes Paid IncomeTaxesPaid	228000
	us-gaap	Income Taxes Paid IncomeTaxesPaid	20000
	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	4907000
	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	4377000
	neo	Share Based Compensation And Warrants ShareBasedCompensationAndWarrants	1907000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	9424000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2930000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	844000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	351000
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	1482000
CY2016Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	642000
CY2016Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	619000
CY2016Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	586000
CY2016Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	52805000
CY2016Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	1818000
CY2016Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	7264000
CY2016Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	5771000
CY2016Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	5771000
CY2016Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	5771000
CY2016Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	5726000
CY2016Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	50225000
CY2016Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	161000
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
	neo	Number Of Customers NumberOfCustomers	2
CY2016Q3	us-gaap	Deferred Tax Assets Liabilities Net Current DeferredTaxAssetsLiabilitiesNetCurrent	8500000
CY2015Q4	us-gaap	Deferred Tax Assets Liabilities Net Current DeferredTaxAssetsLiabilitiesNetCurrent	16668000
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000
CY2015Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	890000
CY2014Q4	us-gaap	Goodwill Goodwill	2929000
CY2015	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	143492000
	us-gaap	Goodwill Purchase Accounting Adjustments GoodwillPurchaseAccountingAdjustments	-242000
CY2016Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	88912000
CY2016Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	6566000
CY2015Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	88912000
CY2015Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1112000
CY2016Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1800000
CY2015Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	93000
CY2016Q3	us-gaap	Long Term Debt LongTermDebt	54813000
	neo	Debt Issuance Costs Net DebtIssuanceCostsNet	1973000
CY2016Q3	us-gaap	Sales Revenue Services Gross SalesRevenueServicesGross	114902000
CY2015Q3	us-gaap	Sales Revenue Services Gross SalesRevenueServicesGross	57192000
	us-gaap	Sales Revenue Services Gross SalesRevenueServicesGross	376857000
	us-gaap	Sales Revenue Services Gross SalesRevenueServicesGross	167525000
CY2016Q3	neo	Contractual Adjustments And Discounts ContractualAdjustmentsAndDiscounts	54141000
CY2015Q3	neo	Contractual Adjustments And Discounts ContractualAdjustmentsAndDiscounts	32066000
	neo	Contractual Adjustments And Discounts ContractualAdjustmentsAndDiscounts	193264000
	neo	Contractual Adjustments And Discounts ContractualAdjustmentsAndDiscounts	95002000
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5326505
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2542527
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	3.32
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5215862
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1162128
	neo	Allocated Share Based Compensation Expense Benefit AllocatedShareBasedCompensationExpenseBenefit	1734000
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	2395015
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	258155
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.07
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.61
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	7.10
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.67
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	3.74
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.011
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	2.56
CY2016Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	8200000
CY2015Q3	neo	Allocated Share Based Compensation Expense Benefit AllocatedShareBasedCompensationExpenseBenefit	828000
	neo	Allocated Share Based Compensation Expense Benefit AllocatedShareBasedCompensationExpenseBenefit	4034000
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y6M
CY2016Q3	neo	Allocated Share Based Compensation Expense Benefit AllocatedShareBasedCompensationExpenseBenefit	1686000

Files In Submission

Name	View Source	Status
0001564590-16-027730-index-headers.html	Edgar Link	pending
0001564590-16-027730-index.html	Edgar Link	pending
0001564590-16-027730.txt	Edgar Link	pending
0001564590-16-027730-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
neo-10q_20160930.htm	Edgar Link	pending
neo-20160930.xml	Edgar Link	completed
neo-20160930.xsd	Edgar Link	pending
neo-20160930_cal.xml	Edgar Link	unprocessable
neo-20160930_def.xml	Edgar Link	unprocessable
neo-20160930_lab.xml	Edgar Link	unprocessable
neo-20160930_pre.xml	Edgar Link	unprocessable
neo-ex1051_265.htm	Edgar Link	pending
neo-ex1052_264.htm	Edgar Link	pending
neo-ex311_8.htm	Edgar Link	pending
neo-ex312_6.htm	Edgar Link	pending
neo-ex321_7.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NEO
NEOGENOMICS INC Stock $neo

2016 Q3 Form 10-Q Financial Statement

#000156459016027730 Filed on November 07, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NEO NEOGENOMICS INC Stock $neo

2016 Q3 Form 10-Q Financial Statement

#000156459016027730 Filed on November 07, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NEO
NEOGENOMICS INC Stock $neo